Komori
Alfresa Holdings (2784) · RiskFirst stated

New drug development and launch risks arising from the U.S. most-favored-nation drug pricing policy

First written in FY2026. . Latest entry: FY2026.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Impact of US Most-Favored-Nation Drug Pricing Policy on New Drug Development and LaunchA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026First statedAnnual report

    「At the same time, we recognize that the U.S. most-favored-nation (MFN) drug pricing policy could reduce market visibility and constitute a risk factor that could adversely affect new drug development and launches in Japan.」

    The U.S. most-favored-nation drug pricing policy under consideration was identified for the first time as an external risk that could reduce market predictability and affect new drug development and launches in Japan.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Alfresa Holdings yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.